Antoine Ouziel

Antoine Ouziel

Auto-generated profile, based on publicly available information

Antoine Ouziel

Pediatric Infectious Pathology Group of the French Pediatric Society, Paris, France; Pediatric Emergency and Intensive Care Service. Hôpital Femme Mère Enfant, Hospices Civils de Lyon, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Clinical Chemistry
Verified
Journal Article
Open access
STSophie Trouillet-Assant
Sophie Trouillet-Assant
SVSebastien Viel
Sebastien Viel
AOAntoine Ouziel
Antoine Ouziel
LBLucille Boisselier
Lucille Boisselier
PRPhilippe Rebaud
Philippe Rebaud
MPMagali Perret
Magali Perret
Background: Fever is one of the leading causes of consultation in the pediatric emergency department for patients under the age of 3 years. Distinguishing between bacterial and viral infections etiologies in febrile patients remains challenging. We hypothesized that specific host biomarkers for viral infections, such as type I-interferon (IFN), could help clinicians’ decisions and limit antibiotic overuse. Methods: Paxgene tubes and serum were collected from febrile children (n = 101), age from 7 days to 36 months, with proven viral or bacterial infections, being treated at pediatric emergency departments in France. We assessed the performance of an IFN signature, which was based on quantification of expression of IFN-stimulated genes using the Nanostring® technology and plasma IFN-α quantified by digital ELISA technology. Results: Serum concentrations of IFN-α were below the quantification threshold (30 fg/mL) for 2% (1/46) of children with proven viral infections and for 71% (39/55) of children with bacterial infections (P < 0.001). IFN-α concentrations and IFN score were significantly higher in viral compared to bacterial infection (P < 0.001). There was a strong correlation between serum IFN-α concentrations and IFN score (p-pearson = 0.83). Both serum IFN-α concentration and IFN score robustly discriminated (Area Under the Curve >0.91 for both) between viral and bacterial infection in febrile children, compared to C-reactive protein (0.83). Conclusions: IFN-α is increased in blood of febrile infants with viral infections. The discriminative performance of IFN-α femtomolar concentrations as well as blood transcriptional signatures could show a diagnostic benefit and potentially limit antibiotic overuse. Clinical Trials Registration: clinicaltrials.gov (NCT03163628).

19 September 2023 in Infectious Diseases Now
Verified
Journal Article
Closed access
YGYves Gillet
Yves Gillet
MLMathie Lorrot
Mathie Lorrot
PMPhilippe Minodier
Philippe Minodier
AOAntoine Ouziel
Antoine Ouziel
HHHervé Haas
Hervé Haas
RCRobert Simon Cohen
Robert Simon Cohen

11 September 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
AFApolline Furgier
Apolline Furgier
CBCamille Brehin
Camille Brehin
CLCorinne Levy
Corinne Levy
RBRomain Basmaci
Romain Basmaci
ELElise Launay
Elise Launay
SWSebastien Walser
Sebastien Walser
Nirsevimab was first introduced in September 2023, showing strong real-world effectiveness in preventing hospitalised RSV-bronchiolitis. RSV-A circulation predominated during 2023–2024, whereas RSV-B was frequent in 2024–2025. Recent reports indicated resistance to nirsevimab in RSV-B strains in France. We aimed to assess the effectiveness of large-scale nirsevimab implementation against hospitalised RSV-bronchiolitis during high RSV-B circulation. A test-negative case-control study was conducted using a national hospital-based surveillance system. All children <12 months hospitalised for bronchiolitis and tested for RSV in 12 French hospitals from October 10, 2024 to March 15, 2025, were included. Cases were RSV-positive bronchiolitis; controls were RSV-negative bronchiolitis. Effectiveness was assessed by a multivariable logistic regression model adjusted for confounders (sex, gestational age at birth, birth weight, risk factors for severe bronchiolitis, month of diagnosis, and medical centre). A range of sensitivity analyses was conducted. 1270 patients were included; among which 830 (65.3%) were RSV-positive and 440 (34.7%) were RSV-negative bronchiolitis. The male-to-female sex ratio was 1.35, and the median age was 3 months (IQR: 1.5–5.6). Among cases, 182 (22.0%) received nirsevimab, compared to 282 (64.1%) for controls. Adjusted effectiveness against RSV-bronchiolitis was 84.9% (95% CI, 80.0–88.6). Subgroup analyses by age and severity (intensive care unit admission, respiratory support) showed consistent results, along with sensitivity analyses. Despite high RSV-B circulation, which has recently been identified to carry mutations potentially inducing resistance to nirsevimab, the effectiveness of the second national nirsevimab campaign against hospitalisation for RSV-bronchiolitis remained high. The study received financial support from 10.13039/100031283 Sanofi , 10.13039/501100014088 AstraZeneca , and the 2023 ATIP-Avenir grant from the 10.13039/501100001677 National Institute of Health and Medical Research (Inserm) .